DDInter596 DDInter1400
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Doxorubicin {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Pazopanib
Doxorubicin {u} (Compound) upregulates {v} (Gene) STK10
STK10 {u} (Gene) is bound by {v} (Compound) Pazopanib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Pazopanib
Doxorubicin {u} (Compound) downregulates {v} (Gene) PLK4
PLK4 {u} (Gene) is bound by {v} (Compound) Pazopanib
Doxorubicin {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Doxorubicin {u} (Compound) upregulates {v} (Gene) RELB
RELB {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Doxorubicin {u} (Compound) upregulates {v} (Gene) FUT1
FUT1 {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Doxorubicin {u} (Compound) upregulates {v} (Gene) FGFR2
FGFR2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Doxorubicin (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Pazopanib (Compound)
Doxorubicin (Compound) upregulates STK10 (Gene) and STK10 (Gene) is bound by Pazopanib (Compound)
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Doxorubicin (Compound) downregulates PLK4 (Gene) and PLK4 (Gene) is bound by Pazopanib (Compound)
Doxorubicin (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Pazopanib (Compound)
Doxorubicin (Compound) upregulates RELB (Gene) and RELB (Gene) is upregulated by Pazopanib (Compound)
Doxorubicin (Compound) upregulates FUT1 (Gene) and FUT1 (Gene) is downregulated by Pazopanib (Compound)
Doxorubicin (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Pazopanib (Compound)
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Doxorubicin (Compound) upregulates FGFR2 (Gene) and FGFR2 (Gene) is bound by Pazopanib (Compound) and FGFR2 (Gene) is downregulated by Pazopanib (Compound)